REGENXBIO Inc. Faces Class Action Lawsuit Over Securities Law Violations

In a significant legal development, REGENXBIO Inc. (NASDAQ: RGNX) is currently embroiled in a class action lawsuit filed by the DJS Law Group. The lawsuit raises serious allegations of violations pertaining to the Securities Exchange Act of 1934, specifically sections 10(b) and 20(a), along with Rule 10b-5 enforced by the U.S. Securities and Exchange Commission (SEC). This class action concerns investors who acquired shares during a specified period, from February 9, 2022, to January 27, 2026, and it aims to address potential losses incurred during that time.

The lawsuit stems from claims that REGENXBIO made numerous misleading statements regarding its product candidate RGX-111. The company repeatedly assured the market about the safety and efficacy of this treatment, only to later conceal critical adverse information that raised concerns regarding its overall safety profile. This alleged deception reached a critical point when a clinical trial participant reportedly developed a tumor, prompting the Food and Drug Administration (FDA) to impose a clinical hold on the RGX-111 trials.

This development has triggered serious concerns among investors. The complaint asserts that REGENXBIO’s persistent positive outlook on RGX-111 was not only misleading but also materially false throughout the class period. Shareholders who believe they were misled are urged to connect with DJS Law Group, as the firm seeks to appoint a lead plaintiff to represent the collective interests of affected investors. It is important to note, however, that joining the lawsuit as a lead plaintiff is not a prerequisite for shareholders to potentially recover their losses under the settlement.

As part of its commitment to supporting investors, the DJS Law Group emphasizes its focus on enhancing returns through balanced legal counseling and aggressive advocacy. They specialize in handling cases related to securities class actions and corporate governance issues, serving some of the world’s largest hedge funds and sophisticated asset managers. This case is just one of many where the firm aims to advocate for investors’ rights and recover losses incurred due to alleged corporate wrongdoing.

Investors have until April 14, 2026, to join the case. Missing this deadline could bar them from recovering potential losses stemming from the alleged violations. For those affected, participating in this litigation could provide an avenue for redress against what they perceive to be corporate misconduct.

In summary, the REGENXBIO class action highlights essential investor rights and the critical nature of truthful disclosure in the biotechnology industry. As stakeholders await further developments in this case, the DJS Law Group stands ready to assist investors in navigating the complexities associated with this class action lawsuit. Those interested in proceeding or seeking more information are encouraged to contact DJS Law Group directly.

As this situation develops, investors are reminded to remain vigilant regarding their investments in REGENXBIO and similar companies, ensuring that they are informed and protected under current securities laws.